http://www.bloomberg.com/apps/news?pid=newsarchive&sid=ajNxrwdCv2Vg Nov. 25 (Bloomberg) -- Roche Holding AG’s arthritis and lymphoma medicine Rituxan cut the need for insulin treatment among patients with type 1 diabetes after a year, a study found
(
Read more... )
Comments 1
Reply
Leave a comment